Kahn Swick & Foti, LLC has launched an investigation into the proposed acquisition of Arcosa, Inc. (NYSE: ACA) by CRH (NYSE: CRH). The law firm is scrutinizing the adequacy of both the consideration offered and the process that led to the transaction agreement.

Under the terms of the proposed deal, Arcosa shareholders are set to receive $150.00 in cash for each share held. The investigation aims to determine whether this fixed cash consideration undervalues the company or if the process failed to maximize shareholder value.

What the Numbers Show

The core of the legal inquiry rests on a single disclosed metric: the $150.00 per share exit price. Without additional financial data such as book value, recent trading ranges, or comparable transaction multiples provided in the source, the analytical focus remains entirely on the sufficiency of this specific offer amount relative to the company's intrinsic worth.

Shareholder Rights

Lewis S. Kahn, Managing Partner at Kahn Swick & Foti, LLC, which includes former Louisiana Attorney General Charles C. Foti, Jr., is leading the review. The firm is seeking to identify if the transaction terms were fair and if the board fulfilled its fiduciary duties during the sale process.

Shareholders who believe the $150.00 offer undervalues Arcosa or wish to discuss their legal options may contact the firm without obligation or cost. Inquiries can be directed via email to lewis.kahn@ksfcounsel.com or by calling 833-538-3612. Further details on the case are available through the firm's official channels.

Investor rights law firm Halper Sadeh LLC has announced it is investigating three publicly listed companies — Arcosa, Inc., Crinetics Pharmaceuticals, Inc., and Leggett & Platt, Incorporated — for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders. The investigations relate to proposed sale transactions involving each company and raise concerns about whether shareholders are receiving fair value and adequate disclosures.

Transactions Under Scrutiny

The firm's investigations span three separate proposed deals across different sectors. Key details of each transaction are outlined below:

In the case of Leggett & Platt, upon closing of the proposed transaction, Leggett & Platt shareholders will own approximately 9% of the combined company.

Key Concerns Raised

Halper Sadeh LLC has highlighted several areas of concern across these transactions:

• Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
• The proposed transactions may contain terms that could limit superior competing offers.
• Shareholders may not have received sufficient disclosures and information to make fully informed decisions.

Potential Relief Sought

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits. The firm represents investors globally who have been affected by securities fraud and corporate misconduct, and states that its attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Shareholders of Arcosa, Crinetics Pharmaceuticals, and Leggett & Platt are encouraged to contact the firm to discuss their rights and options. The firm indicates it would handle any matter on a contingent fee basis, whereby shareholders would not be responsible for out-of-pocket payment of legal fees or expenses.